GAMA
SRPT icon

Graticule Asia Macro Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Graticule Asia Macro Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,000
Closed -$1.04M – 140
2016
Q3 		$1.04M Buy
+17,000
New +$514K 0.07% 82
2016
Q2 		– Sell
-35,000
Closed -$683K – 86
2016
Q1 		$683K Buy
+35,000
New +$612K 0.05% 73

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Graticule Asia Macro Advisors's SRPT Position: Q3 2018 in Review

Graticule Asia Macro Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 55,000 shares — an estimated $7.27M sold.

Graticule Asia Macro Advisors first reported a position in SRPT in Q4 2015 and held it in 7 quarters. The position peaked at $7.27M in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Graticule Asia Macro Advisors reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 55,000 Sarepta Therapeutics shares in Q3 2018, an estimated $7.27M.
  • Graticule Asia Macro Advisors first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 7 quarters.
  • Graticule Asia Macro Advisors's Sarepta Therapeutics position peaked at $7.27M in Q2 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.